Fenoll, AsunciónArdanuy Tisaire, María CarmenLiñares Louzao, JosefinaCercenado, EmiliaMarco Reverté, FrancescFleites, AnaRodríguez Mayo, MaríaLópez Hontangas, Jose LuisPalop, BegoñaAller, Ana IsabelBuendía, BuenaventuraMéndez, CristinaCifuentes, IsabelODIN Study Group2020-04-222020-04-222018-11-160264-410Xhttps://hdl.handle.net/2445/156783Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccina- tion strategies. The aim of this study was to assess the epidemiology of IPD in adults (!18 years) after PCV13 introduction for children: serotypes, clonal complexes, antibiotic non-susceptibility and clinical presentations. We performed a prospective, clinical surveillance of hospitalized culture-confirmed IPDs in adults in nine Spanish hospitals (August 2010-June 2015). A total of 1087 culture-confirmed IPD episodes were included, of which 772 (71.0%) had bacteremic pneumonia (401 complicated/371 uncomplicated pneu- monia), 122 (11.2%) meningitis, 102 (9.4%) non-focal bacteremia, 34 (3.1%) peritonitis and 57 (5.3%) others. The most common serotypes were: 3 (12.7%), 19A (8.5%), 8 (7.7%), 7F (6.3%), 1 (4.2%), 6C (4.2%), 11A (4.2%), 22F (4.2%) and 14 (4.0%). Vaccine types (PCV13 + 6C) caused 49.8% of IPD episodes, with a significant decrease over the 5-year period, and significant decreases in serotypes 6C and 7F. The most common genotypes were: CC180 (8.4%), CC191 (6.0%), and CC53 (5.0%). Vaccine types caused 53.9% (414/768) pneumonia episodes and 58.9% (235/399) complicated pneumo- nia, 53.4% IPD in adults <50 years (143/268), and 54.7% IPD in immunocompetent patients (337/616). Overall non-susceptibility was 25.9% to penicillin (1.1% for parenteral criteria), 24.9% to erythromycin and 2.7% to levofloxacin. Conclusions: Although the percentage of vaccine-types causing IPDs in adults significantly decreased, it remained high. Associations of vaccine types with pneumonia (with complicated pneumonia for specific serotypes), and immunocompetent patients point to the burden of IPD caused by PCV13 serotypes.8 p.application/pdfengcc-by-nc-nd (c) Elsevier B.V., 2018http://creativecommons.org/licenses/by-nc-nd/3.0/esPneumòniaPneumococsPneumoniaStreptococcus pneumoniainfo:eu-repo/semantics/article6888912020-04-22info:eu-repo/semantics/openAccess